NKNaoshi Kondo

Naoshi Kondo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoshi Kondo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Negi

    Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

    19 shared publications
  • Shigeru Honda

    Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

    10 shared publications
  • Shigeru Honda

    Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

    9 shared publications
  • Hiroaki Bessho

    Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

    8 shared publications
  • Yasutomo Tsukahara

    8 shared publications
  • Akiko Miki

    Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

    4 shared publications

Latest Publications

  • Nrf2 signaling modulates cigarette smoke-induced complement activation in retinal pigmented epithelial cells

    by Lei Wang, Naoshi Kondo, Marisol Cano, Katayoon Ebrahimi, Takeshi Yoshida, Bradley P. Barnett, Shyam Biswal, James T. Handa


  • Common Variants in the Complement Factor H Gene Confer Genetic Susceptibility to Central Serous Chorioretinopathy

    by Akiko Miki, Naoshi Kondo, Suiho Yanagisawa, Hiroaki Bessho, Shigeru Honda, Akira Negi


  • The Association ofAge-related Maculopathy Susceptibility 2 (ARMS2)andComplement Factor H (CFH)Variants with Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

    by Akiko Miki, Shigeru Honda, Naoshi Kondo, Akira Negi

    Purpose: To compare the association of age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) variants between two different angiographic phenotypes of polypoidal choroidal vasculopathy (PCV). Methods: We included 175 Japanese patients with PCV and 150 age- and sex-matched controls. PCV was classified into two phenotypes (Type 1 and Type 2) according to the presence or absence of the feeding vessels found in indocyanine-green angiography. The single nucleotide polymorphism (SNP) at rs10490924 (A69S) in ARMS2 and rs800292 (I62V), rs1061170 (Y402H) in the CFH region were genotyped using the TaqMan assay. Results: The minor allele frequency (MAF) of rs10490924 was significantly different between Type 1 PCV (n = 81) and control (p < 0.0001), while no difference was found between Type 2 PCV (n = 94) and control (p = 0.20). The MAF of rs800292 was significantly different between each type of PCV and control (p < 0.0001 and 0.0001 for Type 1 versus control and Type 2 versus control, respectively). The MAF of rs1061170 was not significantly different between either type of PCV and control (p = 0.084 and 0.15, respectively). Conclusions: There may be significantly different associations in the genetic variants of ARMS2 between two angiographic phenotypes of PCV.


    • 22 November 2012
      • Vol. 18, 2796-2804
    Open Access

    Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy

    by Shigeru Honda, Hiroaki Bessho, Naoshi Kondo, Sentaro Kusuhara, Yasutomo Tsukahara, Akira Negi

    To clarify the association between cluster of differentiation 36 (CD36) gene polymorphisms and the response to photodynamic therapy (PDT) in polypoidal choroidal vasculopathy (PCV). One hundred and thirty-seven patients with PCV were enrolled. The patients were treated with PDT and followed up for more than 6 months. Retreatments were performed every 3 months as needed based on findings from angiography. Patients who showed an improvement in their best-corrected visual acuity at 6 months post-PDT were classified as PDT responders, and the others were defined as non-responders. For the 73 responders and 64 non-responders, 19 single nucleotide polymorphisms (SNPs) across the CD36 region were genotyped using the TaqMan assay. We analyzed the association between these variants and the visual outcomes of PDT. The allelic frequencies of the SNPs rs3211851, rs3173798, and rs3211908 showed nominally significant differences between the PDT responders and non-responders. Genotype association analysis revealed a significant association of SNP rs3173798 with the visual outcome of PDT in a dominant model. The presence of the C allele in rs3173798 was significantly associated with a poor response to PDT after multivariate logistic regression analysis with clinical pre-PDT parameters. The mean best-corrected visual acuity in the group with the TT genotype of rs3173798 was significantly improved over 12 months of follow-up after the initial PDT. The coding variants in CD36 are possibly associated with the visual outcome of PDT in patients with PCV.


    • 18 January 2012
      • Vol. 18, 121-127
    Open Access

    The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration

    by Hiroaki Bessho, Shigeru Honda, Naoshi Kondo, Sentaro Kusuhara, Yasutomo Tsukahara, Akira Negi

    To clarify the association of cluster of differentiation 36 (CD36) variants with polypoidal choroidal vasculopathy (PCV) and compare them with those in typical neovascular age-related macular degeneration (tAMD). We included 349 Japanese AMD patients (210 PCV, 139 tAMD) and 198 age-matched controls. Four tag single-nucleotide polymorphisms (SNPs)—rs10499862, rs3173798, rs3211883, and rs3173800—in the CD36 region were genotyped using the TaqMan assay. Allelic and genotypic frequencies of the SNPs were tested. Although none of the SNPs tested were associated with PCV, the allelic frequencies of rs3173798 and rs3173800 were significantly different between PCV and tAMD patients. Genotype association analysis demonstrated different associations of these two SNPs between PCV and tAMD in the genotype model. Haplotype analysis revealed that the association of the major haplotype (T-T-T-T) at four selected SNPs in CD36 differed significantly between PCV and tAMD patients. The CD36 region may be associated with the difference in genetic susceptibility for PCV and tAMD.


    • 31 December 2011
      • Vol. 17  (383-85) , 3574-3582
    Open Access

    Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2)

    by Suiho Yanagisawa, Naoshi Kondo, Akiko Miki, Wataru Matsumiya, Sentaro Kusuhara, Yasutomo Tsukahara, Shigeru Honda, Akira Negi

    Purpose: To investigate whether the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2) has a different hereditary contribution in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Methods: We initially conducted a comparative genetic analysis of neovascular AMD and PCV, genotyping the ARMS2 A69S variant in 181 subjects with neovascular AMD, 198 subjects with PCV, and 203 controls in a Japanese population. Genotyping was conducted using TaqMan technology. Results were then integrated into a meta-analysis of previous studies representing an assessment of the association between the ARMS2 A69S variant and neovascular AMD and/or PCV, comprising a total of 3,828 subjects of Asian descent. The Q-statistic test was used to assess between-study heterogeneity. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a fixed effects model. Results: The genetic effect of the A69S variant was stronger in neovascular AMD (allelic summary OR=3.09 [95% CI, 2.71-3.51], fixed effects p<0.001) than in PCV (allelic summary OR=2.13 [95% CI, 1.91-2.38], fixed effects p<0.001). The pooled risk allele frequency was significantly higher in neovascular AMD (64.7%) than in PCV (55.6%). The population attributable risks for the variant allele were estimated to be 43.9% (95% CI, 39.0%-48.4%) and 29.7% (95% CI, 25.4%-34.0%) for neovascular AMD and PCV, respectively. No significant between-study heterogeneity was observed in any statistical analysis in this meta-analysis. Conclusions: Our meta-analysis provides substantial evidence that the ARMS2 A69S variant confers a significantly higher risk of neovascular AMD than PCV. Furthermore, there is compelling evidence that the risk attributable to the A69S variant differs between geographic atrophy and neovascular AMD. Together with defining the molecular basis of susceptibility, understanding the relationships between this genomic region and disease subtypes will yield important insights, elucidating the biologic architecture of this phenotypically heterogeneous disorder.


  • Open Access

    A Common Complement C3 Variant Is Associated with Protection against Wet Age-Related Macular Degeneration in a Japanese Population

    by Suiho Yanagisawa, Naoshi Kondo, Akiko Miki, Wataru Matsumiya, Sentaro Kusuhara, Yasutomo Tsukahara, Shigeru Honda, Akira Negi

    Genetic variants in the complement component 3 gene (C3) have been shown to be associated with age-related macular degeneration (AMD) in Caucasian populations of European descent. In particular, a nonsynonymous coding variant, rs2230199 (R102G), is presumed to be the most likely causal variant in the C3 locus based on strong statistical evidence for disease association and mechanistic functional evidence. However, the risk allele is absent or rare (C3 are associated with wet AMD, a common advanced-stage manifestation of AMD, in a Japanese population. We genotyped 13 tag single nucleotide polymorphisms (SNPs) that capture the majority of common variations in the C3 locus and tested for associations between these SNPs and wet AMD in a Japanese population comprising 420 case subjects and 197 controls. A noncoding variant in C3 (rs2241394) exhibited statistically significant evidence of association (allelic P = 8.32×10−4; odds ratio = 0.48 [95% CI = 0.31–0.74] for the rs2241394 C allele). Multilocus logistic regression analysis confirmed that the effect of rs2241394 was independent of the previously described loci at ARMS2 and CFH, and that the model including variants in ARMS2 and CFH plus C3 rs2241394 provided a better fit than the model without rs2241394. We found no evidence of epistasis between variants in C3 and CFH, despite the fact that they are involved in the same biological pathway. Our study provides evidence that C3 is a common AMD-associated locus that transcends racial boundaries and provides an impetus for more detailed genetic characterization of the C3 locus in Asian populations.


    • 20 April 2011
      • Vol. 17, 977-982
    Open Access

    The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

    by Hiroaki Bessho, Shigeru Honda, Naoshi Kondo, Akira Negi

    To determine the association of age-related maculopathy susceptibility 2 (ARMS2) gene polymorphisms with the phenotype of typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV) and the effects of photodynamic therapy (PDT). The single nucleotide polymorphisms at rs10490924 (A69S) in ARMS2 of 68 tAMD and 119 PCV patients who underwent PDT were genotyped using the TaqMan assay. The baseline best corrected visual acuity (BCVA) and lesion size were compared among the three genotypes at rs10490924. A multivariate regression analysis was performed to evaluate the influence of the baseline BCVA, greatest linear dimension (GLD), and lesion phenotype (tAMD or PCV) on the association of rs10490924 with the BCVA 12 months after the first PDT. The mean lesion size was significantly different among the GG, GT, and TT genotypes at rs10490924 in the PCV group, although no significant differences were detected in the tAMD group. PCV patients with a G allele had significantly better vision at 3 months after the initial PDT. tAMD patients with a TT genotype had significantly poorer vision at 12 months after the first PDT. In the multivariate regression analysis, the additive model of the G allele at rs10490924 was associated with a significantly better BCVA 12 months after the first PDT in tAMD and PCV patients. ARMS2 variants are likely associated with the phenotype and the effects of PDT in tAMD and PCV.